Advertisement

Research Article Free access | 10.1172/JCI119603

The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets.

K E Bornfeldt, J S Campbell, H Koyama, G M Argast, C C Leslie, E W Raines, E G Krebs, and R Ross

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Bornfeldt, K. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Campbell, J. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Koyama, H. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Argast, G. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Leslie, C. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Raines, E. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Krebs, E. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Washington, Seattle, Washington 98195, USA. bornf@u.washington.edu

Find articles by Ross, R. in: JCI | PubMed | Google Scholar

Published August 15, 1997 - More info

Published in Volume 100, Issue 4 on August 15, 1997
J Clin Invest. 1997;100(4):875–885. https://doi.org/10.1172/JCI119603.
© 1997 The American Society for Clinical Investigation
Published August 15, 1997 - Version history
View PDF
Abstract

Activation of the classical mitogen-activated protein kinase (MAPK) pathway leads to proliferation of many cell types. Accordingly, an inhibitor of MAPK kinase, PD 098059, inhibits PDGF-induced proliferation of human arterial smooth muscle cells (SMCs) that do not secrete growth-inhibitory PGs such as PGE2. In striking contrast, in SMCs that express the inducible form of cyclooxygenase (COX-2), activation of MAPK serves as a negative regulator of proliferation. In these cells, PDGF-induced MAPK activation leads to cytosolic phospholipase A2 activation, PGE2 release, and subsequent activation of the cAMP-dependent protein kinase (PKA), which acts as a strong inhibitor of SMC proliferation. Inhibition of either MAPK kinase signaling or of COX-2 in these cells releases them from the influence of the growth-inhibitory PGs and results in the subsequent cell cycle traverse and proliferation. Thus, the MAPK pathway mediates either proliferation or growth inhibition in human arterial SMCs depending on the availability of specific downstream enzyme targets.

Version history
  • Version 1 (August 15, 1997): No description
Advertisement
Advertisement